Left ventricular unloading during veno-arterial ECMO: a review of percutaneous and surgical unloading interventions

Dirk W. Donker,1 Daniel Brodie,2 José P.S. Henriques3 and Michael Broomé4,5,6

Abstract
Short-term mechanical support by veno-arterial extracorporeal membrane oxygenation (VA ECMO) is more and more applied in patients with severe cardiogenic shock. A major shortcoming of VA ECMO is its variable, but inherent increase of left ventricular (LV) mechanical load, which may aggravate pulmonary edema and hamper cardiac recovery. In order to mitigate these negative sequelae of VA ECMO, different adjunct LV unloading interventions have gained a broad interest in recent years. Here, we review the whole spectrum of percutaneous and surgical techniques combined with VA ECMO reported to date.

Keywords
veno-arterial extracorporeal membrane oxygenation (VA ECMO); left ventricular unloading; cardiogenic shock; cardiovascular modeling; computer simulation

Introduction
The widespread use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) in severe cardiogenic shock is importantly driven by its relative ease of implantation and immediate reversal of inadequate systemic perfusion.1 Yet, clinical management of VA ECMO remains challenging and requires mechanistic insights and careful monitoring of a proper balance between the circulatory needs and the cardiac condition of an individual patient.2 Although, VA ECMO allows full circulatory support to counteract a severe shock state, the continuous, extracorporeal blood flow and increased aortic pressure are opposed to the ejection of the native, failing heart.

It is increasingly recognized that VA ECMO, especially peripheral VA ECMO, may significantly increase left ventricular (LV) afterload through retrograde infusion of arterialized blood into the descending aorta.1–4 As a consequence of this inherent limitation of VA ECMO, the myocardium is overloaded (Figure 1a) and the impaired LV dilates, while increased filling pressures and pulmonary edema ensue. All these adverse sequelae of VA ECMO not only significantly limit cardiac recovery, but also negatively impact on long-term prognosis.5,6

In order to minimize LV overload and support recovery of the failing heart during VA ECMO, different percutaneous and surgical adjunct interventions to VA ECMO have been proven to be useful in clinical practice, as recently also supported by comprehensive cardiovascular modeling and computer simulation.2,7

Intra-aortic balloon pump combined with VA ECMO
The intra-aortic balloon pump (IABP) has been used as an adjunct to VA ECMO for almost two decades and in

1Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, New York, NY, USA
3Department of Cardiology, Academic Medical Center, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
4ECMO Department, Karolinska University Hospital, Stockholm, Sweden
5Anaesthesiology and Intensive Care, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden
6School of Technology and Health, Royal Institute of Technology, Stockholm, Sweden

Corresponding author:
Michael Broomé, ECMO Department, Karolinska University Hospital, Stockholm, SE-171 76, Sweden.
Email: michael.broome@ki.se
more than 2,500 patients reported in the literature (supplemental Table 1 and supplemental Figure 1) in order to create pulsatile flow and afterload reduction. In post-cardiotomy, post heart transplantation and medical V A ECMO indications, including refractory cardiac arrest, concomitant IABP has been considered to be an independent predictor of improved survival and facilitates weaning from V A ECMO.8–12 Therefore, some authors have advocated the use of an IABP for all patients on V A ECMO, although this strategy has not universally been agreed upon.8,10,11 Recent clinical data are conflicting and partly contrast this notion for post-cardiotomy failure, infarct-related shock and other clinical settings based on extensive analyses that do not unequivocally support the routine combination of VA ECMO and IABP as a clinical standard,13–15 whereas another recent analysis favors its application and suggests a survival benefit.16 Mechanistically, it has been shown that the combined use can enhance patients' blood flow in the native coronary arteries as well as in bypass grafts, although this has been questioned in an experimental setting and may importantly depend on the VA ECMO configuration, cannulation sites and cannula direction.17–19 The IABP may also negatively impact on the spinal cord and cerebral blood flow during VA ECMO, especially when the native cardiac function is severely impaired, while experimental studies challenge this notion.19–21 Moreover, experimental work on the combined use has demonstrated an improved myocardial oxygen-supply-demand balance in central and peripheral VA ECMO,22 whereas a beneficial impact on the microcirculation seems to be lacking.23,24 From a theoretical perspective, the introduction of an IABP during VA ECMO could be expected to reduce the mean systemic impedance, systolic pressure and peak LV wall stress by 10-15%25 (Figure 1b). Therefore, adjunct use of the IABP may be indicated in a persistently non-ejecting LV during peripheral or central V A ECMO support, where LV thrombosis is impending and systolic afterload reduction may allow aortic valve opening and switching to alternative cardiac mechanical support is not desired or possible.21,26-28 Moreover, clinical studies focusing on beneficial effects of the adjunct IABP on LV filling pressures have reported reduced central venous pressure, pulmonary capillary wedge pressure (PCWP), smaller LV dimensions and less pulmonary edema on chest x-ray.24,29,30 This may not only have a beneficial effect on pulmonary edema, which is thought to complicate at least 30% of VA ECMO treatments, but translate into improved prognosis, even after successful bridge-to-bridge long-term LVAD strategies.5,6,29 In summary, the LV unloading effect of an IABP during VA ECMO is rather limited and the PCWP decrease has been reported to reach maximally 5 mmHg, which is supported by clinical experience and computer simulations (Supplemental data/file 2).7,17,24

Figure 1. a. LV pressure-volume loops in normal physiology (red), severe systolic left heart failure (dark red) and when systemic circulation is supported by VA ECMO 4 L/min (black). Right shift of the loop indicates dilatation, which is worsened with VA ECMO, mainly due to an increase in afterload. b. LV pressure-volume loops in severe left heart failure supported by VA ECMO 4 L/min (black) in conjunction with different support modalities aimed at LV unloading. Intra-aortic balloon pumping (blue) results in increasing stroke volumes, with a modest unloading effect, while LV venting into the ECMO system (dark red) achieves better unloading. Atrial septostomy (red) achieves efficient LV unloading, but results in smaller stroke volumes, while the most effective unloading is seen with the Impella® (green). For further details, see main text.
Percutaneous trans-aortic LV assist device Impella® combined with VA ECMO

The Impella® (Abiomed, Danvers, MA) is a trans-aortic LV assist device designed as a catheter-based, microaxial impeller pump that provides continuous blood flow from the LV into the ascending aorta. The 2.5 device provides up to 2.5 L/min blood flow and is intended for percutaneous short-term mechanical support in cardiogenic shock, but may lack sufficient blood flow in patients presenting with profound cardiogenic shock, when multi-organ failure is impending and mechanical ventilation is required.32,33

The Impella® 2.5 and the larger CP device have been reported in a number of adult cases (n=151 cases, supplemental Table 1 and supplemental Figure 1) as adjunct to peripheral VA ECMO in order to unload the LV, representing the second largest clinical experience as LV unloading intervention during VA ECMO following the IABP. All available Impella® devices for LV support, i.e., 2.5, CP and the surgical 5.0 device have been combined with VA ECMO and revealed a clear reduction of right atrial pressure, PCWP, LV volumes and pulmonary edema in adults (Figure 1b) and, also, increased pulmonary blood flow and right-ventricular performance in children.37 Moreover, a large retrospective analysis suggested a survival benefit and improved bridging to recovery or additional support therapy when combining the Impella® with VA ECMO.35 The Impella® device should, therefore, be considered as a powerful LV unloading device during VA ECMO, which is also supported by simulation experiments, indicating a maximum reduction of PCWP of 10 mmHg and LV volume of 20% as a function of Impella® flow (Supplemental data/file 2).7

Atrial septostomy during VA ECMO

With an atrial septum bulging from left to right, as visualized on the echocardiogram and indicating higher left-sided than right-sided filling pressures, it is tempting to unload the LV by creating an atrial septal defect.38–40 The favorable effect of such a left-to-right shunt on LV decompression and LV loading conditions has been reported to be significant in neonates,41 children,42–49 and adults,40,43 as supported by experimental data (Figure 1b). Yet, it can be technically difficult to create an appropriately sized defect, which may critically impact on LV unloading and potentially even result in a non-ejecting LV, cavity and aortic root thrombosis (Supplemental data/file 2). Alternatively, a dedicated percutaneous device can be used to create well-defined sizes of the atrial septal defect, allowing trans-catheter exchange of the device as well as replacement with a definite closure device when not needed any longer.46 It should be realized that atrial septostomy has been reported as one of the first LV unloading techniques during VA ECMO, but remains technically demanding and experience is largely confined to specialized centers and pediatric patients41 (supplemental Table 1 and supplemental Figure 1).

Percutaneous trans-septal left atrial pulmonary artery and trans-aortic LV venting during VA ECMO

A percutaneous approach to vent the LV by cannulation via the interatrial septum has successfully been applied in children42,45,47–49 and adults48,50–52 and has, as the atrial septostomy, already been reported in the 1990s53 (supplemental Table 1 and supplemental Figure 1). It is understandable that the LV venting effect of a cannula in the left atrium is very comparable to an atrial septostomy, as described above. Yet, the blood flow drained to the venous side of the ECMO circuit importantly depends on the sizing of the cannula and tubing48,51 and flow can potentially be controlled by a separate pump and, also, temporarily be clamped during weaning. In practice, it seems that using a 22F cannula can offer a potent, yet variable degree of LV unloading with a PCWP reduction ranging between 4 mmHg and 17 mmHg.52 If the draining cannula is advanced through the mitral valve into a non-ejecting LV, ventricular drainage will assure circulation of blood in the LV cavity and decrease the risk of flow stagnation and cavity thrombosis. Alternatively, the percutaneous route can also be used to access the LV via a trans-aortic catheter, as proposed in experimental and clinical studies in a very limited number of cases via an axillary or femoral artery approach54–56 (supplemental Table 1 and supplemental Figure 1). An indirect technique using a trans-pulmonary artery catheter can be adopted for LV venting, which is based on experimental findings57,58 and clinical studies in children and adults.59–61 It is important to realize that pulmonary artery venting may, theoretically, result in decreased flow in the pulmonary circulation, resulting in ischemia of the lung and, therefore, implicates close monitoring of pulmonary artery flow and/or end-tidal CO₂.62

Direct surgical LV, LA and pulmonary artery venting during VA ECMO

A direct surgical approach to unloading the LV requires an apical vent or a venting cannula introduced via the right superior pulmonary vein or, exceptionally, the pulmonary artery, which requires sternotomy or thoracotomy, although minimally invasive approaches have been suggested.42,63–67 Although, the experience reported in the literature is relatively limited (supplemental Table 1 and supplemental Figure 1), this might not hold for the
regular practice of the technique in selected cardiothoracic surgical centers.

Surgical venting techniques use larger-sized cannulae compared to percutaneous approaches, which, in turn, allow improved venous drainage and substantial LV unloading, as supported by clinical experimental data (Figure 1b) (supplemental Table 1 and supplemental Figure 1), yet remain to carry substantial risks of bleeding.68 In addition, patient care and mobilization in the ICU is challenging.68 Short-term use of venting postcardiomyotomy as an adjunct to central arterial cannulation is supported by some authors, despite considerable mortality and complication rates.42,67

Alternatively, it has been proposed to anticipate temporary LV assist-device implantation upon initiation of VA ECMO, including adequate LV venting.66,69 In this sense, it can be considered to use a large-sized LV apical vent with a minimum of a 32-F drainage cannula. Venous drainage of the VA ECMO circuit can be accomplished by percutaneous venous drainage, while aortic access is obtained with a 10-mm Dacron graft on the ascending aorta. This configuration allows tailoring of LV venting and RV drainage, using adjustable clamps and blood flow meters mounted on the circuit tubing. When right ventricular and pulmonary function have recovered sufficiently, this VA ECMO setup can easily be converted at the bedside to a more sustainable temporary LV assist device by simply removing the drainage cannula in the femoral vein.66,70

**Practical implications for clinical decision making**

Peripheral VA ECMO remains the fastest and most reliable method to institute systemic rescue perfusion in life-threatening cardiac low-output states.1 This extracorporeal support strategy provides immediate restitution of organ perfusion and oxygenation and, therefore, enables clinicians to establish a bridge to decision, recovery or alternative therapies in a variety of settings. Yet, it should be realized that outcome is less favorable beyond a few weeks of support due to inherent limitations and the invasiveness of VA ECMO.

Bridging cardiac failure with VA ECMO is challenging and the potential for short-term myocardial recovery will largely depend on the underlying disease and its individual manifestation. Yet, optimal clinical management remains a mainstay of VA ECMO support. Therefore, it should be realized that LV overload during VA ECMO has an estimated incidence of up to 70% of cases and may significantly impact on survival.6,35,71 Clinically, LV overload may initially present as mildly elevated filling pressures, pulmonary edema and increased left-sided cardiac dimensions. Here, the initiation of an adjunct IABP can be considered, based on a large body of practice experience, when aiming to reduce a PCWP of 20 mmHg or less by maximally 5 mmHg7,24 (Figure 1b). When more potent unloading is required, a percutaneous Impella® should be added to the VA ECMO as increasingly reported recently.35,72 The unloading effect of the Impella® is comparable to more technically demanding percutaneous procedures, i.e. atrial septostomy and trans-septal left atrial venting and surgical unloading interventions7 (Figure 1b) (supplemental Table 1 and supplemental Figure 1). In this context, surgical adjunct interventions are especially opportune when patients undergo surgical intervention, i.e. thoracotomy or sternotomy, while the role of percutaneous pulmonary artery or trans-aortic LV venting is unclear, as the reported experience is very limited so far (supplemental Table 1 and supplemental Figure 1).

This LV overload situation may also deteriorate into a life-threatening accumulation of interrelated cardio pulmonary complications, cumulating in pulmonary hemorrhage,65 increasing spontaneous echo contrast “smoke” and LV thrombosis.5,6,26-28 An over-distended LV exposed to high myocardial stress, strain, work and oxygen consumption, as well as reduced coronary blood flow, will likely be unable to recover. Pulmonary edema may primarily occur as a consequence of high LV filling pressures, but systemic inflammation mediated by shock and impending multi-organ failure, as well as blood contact to artificial extracorporeal surfaces, may contribute. In this context, acute lung injury has been shown to significantly impact on prognosis in patients receiving VA ECMO, even after successful bridge-to-bridge therapy.6

Detailed clinical assessment of LV overload may be cumbersome, since its biomechanical impact on the failing myocardium may not be well-represented by standard clinical diagnostics.3,4,7,24,75 In general, repeated echocardiograms, assessment of intra-cardiac filling pressures and monitoring of pulmonary edema are imperative on a daily basis. Yet, the exact indication, timing and LV unloading strategy, i.e. percutaneous or surgical, should further be clarified in clinical studies. In addition, it has recently been demonstrated that the acute hemodynamic effects of all interventions detailed in this review can be simulated in computer models2,4,7,76 (Figure 1ab, Supplemental animation material - animation of heart failure with VA ECMO and unloading interventions). So far, these models, i.e. Aplysia CardioVascular Lab, Harvi and Basel Heart Simulator are scarce and have mainly been used for illustrations and educational purposes when simulating cardiac mechanical support modalities.2,4,7,31,76 These models await further clinical validation and it remains to be determined whether clinical decision-making in individual patients on VA ECMO can be improved by
Conclusion

VA ECMO can provide rapid and adequate cardiovascular support in patients with severe cardiogenic shock. Yet, the occurrence of LV overload during VA ECMO support frequently threatens its clinical success and should, therefore, be treated promptly. Here, we review the whole spectrum of adjunct percutaneous and surgical interventions that have successfully been used in clinical practice to unload the LV. It remains a clinical challenge to foresee which patients will benefit from adjunct interventions as they carry inherent procedural risks and it can be extremely cumbersome to predict the expected degree of LV unloading when intervening in an individual patient.

Declaration of Conflicting Interest

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Michael Broomé is the owner of the company Aplysia Medical AB developing the simulation software Aplysia CardioVascular Lab. Dirk W. Donker has received honoraria for scientific presentations from Maquet Getinge and Medtronic. Daniel Brodie is currently on the medical advisory boards of ALung Technologies and Kadence. All compensation for these activities is paid to Columbia University. For the remaining author none were declared.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Michael Broomé is the owner of the company Aplysia Medical AB developing the simulation software Aplysia CardioVascular Lab. Dirk W. Donker has received honoraria for scientific presentations from Maquet Getinge and Medtronic. Daniel Brodie is currently on the medical advisory boards of ALung Technologies and Kadence. All compensation for these activities is paid to Columbia University. For the remaining author none were declared.

ORCID iDs

Dirk W. Donker https://orcid.org/0000-0001-6496-2768
Michael Broomé https://orcid.org/0000-0002-8987-9909

References

1. Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol 2014; 63: 2769–2778.
2. Burkhoff D, Sayer G, Doshi D, Uriel N. Hemodynamics of mechanical circulatory support. J Am Coll Cardiol 2015; 66: 2663–2674.
3. Rupprecht I, Florchinger B, Schopka S, et al. Cardiac decompression on extracorporeal life support: a review and discussion of the literature. ASAIO J 2013; 59: 547–553.
4. Broomé M, Donker DW. Individualized real-time clinical decision support to monitor cardiac loading during venoarterial ECMO. J Transl Med 2016; 14: 4.
5. Mirabel M, Luyt CE, Leprince P, et al. Outcomes, long-term quality of life, and psychologic assessment of fulminating myocarditis patients rescued by mechanical circulatory support. Crit Care Med 2011; 39: 1029–1035.
6. Boulate D, Luyt CE, Pozzi M, et al. Acute lung injury after mechanical circulatory support implantation in patients on extracorporeal life support: an unrecognized problem. Eur J Cardiothorac Surg 2013; 44: 544–549; discussion 549–550.
7. Donker DW, Brodie D, Henquies JPS, Broomé M. Left ventricular unloading during veno-arterial ECMO: a simulation study. ASAIO J 2018. Mar 10. doi: 10.1097/MAT.0000000000000755. [Epub ahead of print]
8. Smedira NG, Moazami N, Goldman CM, et al. Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: survival at five years. J Thorac Cardiovasc Surg 2001; 122: 92–102.
9. Doll N, Fabricius A, Borger MA, et al. Temporary extracorporeal membrane oxygenation in patients with refractory postoperative cardiogenic shock—a single center experience. J Card Surg 2003; 18: 512–518.
10. Doll N, Kiaii B, Borger M, et al. Five-year results of 219 consecutive patients treated with extracorporeal membrane oxygenation for refractory postoperative cardiogenic shock. Ann Thorac Surg 2004; 77: 151–157; discussion 157.
11. Rastan AJ, Dege A, Mohr M, et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg 2010; 139: 302–311, 311 e1.
12. Ro SK, Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW. Extracorporeal life support for cardiogenic shock: influence of concomitant intra-aortic balloon counterpulsation. Eur J Cardiothorac Surg 2014; 46: 186–192; discussion 192.
13. Park TK, Yang JH, Choi SH, et al. Clinical impact of intra-aortic balloon pump during extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock. BMC Anesthesiol 2014; 14: 27.
14. Cheng R, Hachamovitch R, Makkar R, et al. Lack of survival benefit found with use of intraaortic balloon pump in extracorporeal membrane oxygenation: a pooled experience of 1517 patients. J Invasive Cardiol 2015; 27: 453–458.
15. Lin LY, Liao CW, Wang CH, et al. Effects of additional intra-aortic balloon counter-pulsation therapy to cardiogenic shock patients supported by extra-corporeal membranous oxygenation. Sci Rep 2016; 6: 23838.
16. Aso S, Matsu H, Fushimi K, Yasunaga H. The effect of intraaortic balloon pumping under venoarterial extracorporeal membrane oxygenation on mortality of cardiogenic patients: an analysis using a nationwide inpatient database. Crit Care Med 2016; 44: 1974–1979.
17. Madersbacher N, Liakopoulos OF, Wipperman J, et al. The impact of intraaortic balloon counterpulsation on bypass graft flow in patients with peripheral ECMO. J Card Surg 2009; 24: 265–268.
18. Madershahian N, Wippermann J, Liakopoulos O, et al. The acute effect of IABP-induced pulsatility on coronary vascular resistance and graft flow in critical ill patients during ECMO. J Cardiovasc Surg (Torino) 2011; 52: 411–418.

19. Belohlavek J, Mleek M, Huptych M, et al. Coronary versus carotid blood flow and coronary perfusion pressure in a pig model of prolonged cardiac arrest treated by different modes of venoarterial ECMO and intraaortic balloon counterpulsation. Crit Care 2012; 16: R50.

20. Yang F, Jia ZS, Xing JL, et al. Effects of intra-aortic balloon pump on cerebral blood flow during peripheral venoarterial extracorporeal membrane oxygenation support. J Transl Med 2014; 12: 106.

21. Samadi B, Nguyen D, Rudham S, Barnett Y. Spinal cord infarct during concomitant circulatory support with intra-aortic balloon pump and veno-arterial extracorporeal membrane oxygenation. Crit Care Med 2016; 44: e101–105.

22. Sauren LD, Reesink KD, Selder JL, Beghi C, van der Veen FH, Maessen JG. The acute effect of intra-aortic balloon counterpulsation during extracorporeal life support: an experimental study. Artif Organs 2007; 31: 31–38.

23. Jung C, Fuernau G, de Waha S, et al. Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy. Clin Res Cardiol 2015; 104: 679–687.

24. Petroni T, Harrois A, Amour J, et al. Intra-aortic balloon pump effects on macrocirculation and microcirculation in cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation*. Crit Care Med 2014; 42: 2075–2082.

25. Urschel CW, Eber L, Forrester J, Matloff J, Carpenter R, Donker DW. Peripheral venoarterial extracorporeal membrane oxygenation for myocardial failure. J Cardiovasc Surg (Torino) 2011; 52: 666–668.

26. Moubarak G, Weiss N, Leprince P, Luyt CE. Massive intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. J Heart Lung Circ 2014; 33: 236–238.

27. Delnoij TS, Wetzels AE, Wererink PW, Maessen JG, Caliskan K, Donker DW. Peripheral venoarterial extracorporeal life support despite impending left ventricular thrombosis: a bridge to resolution. J Cardiothorac Vasc Anesth 2013; 27: e48–49.

28. Alhussein M, Moayedi Y, Posada JD, et al. Ventricular thrombosis post-venoarterial extracorporeal membrane oxygenation. Circ Heart Fail 2017; 10.

29. Brechot N, Demondion P, Santi F, et al. Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. Eur Heart J Acute Cardiovasc Med 2017; 4: 1711169.

30. Ma P, Zhang Z, Song T, et al. Combining ECMO with IABP for the treatment of critically ill adult heart failure patients. Heart Lung Circ 2014; 23: 363–368.

31. Burzotta F, Trani C, Doshi SN, et al. Impella ventricular support in clinical practice: collaborative viewpoint from a European expert user group. Int J Cardiol 2015; 201: 684–691.

32. Lauten A, Engstrom AE, Jung C, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail 2013; 6: 23–30.

33. O’Neill WW, Schreiber T, Wohns DH, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol 2014; 27: 1–11.

34. Koeckert MS, Jorde UP, Naka Y, Moses JW, Takayama H. Impella LP 2.5 for left ventricular unloading during venoarterial extracorporeal membrane oxygenation support. J Card Surg 2011; 26: 666–668.

35. Pappalardo F, Schulte C, Pieri M, et al. Concomitant implantation of Impella(R) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 2017; 19: 404–412.

36. Lim HS. The effect of Impella CP on cardiopulmonary physiology during venoarterial extracorporeal membrane oxygenation support. Artif Organs 2017; 41:1109–1112.

37. Vlaselaers D, Desmet M, Desmet L, Meyns B, Jens D. Ventricular unloading with a miniature axial flow pump in combination with extracorporeal membrane oxygenation. Intensive Care Med 2006; 32: 329–333.

38. Johnston TA, Jaggers J, McGovern JJ, O’Laughlin MP. Bedside transseptal balloon dilation atrial septostomy for decompression of the left heart during extracorporeal membrane oxygenation. Catheter Cardiovasc Interv 1999; 46: 197–199.

39. Kotani Y, Chetan D, Rodrigues W, et al. Left atrial decompression during venoarterial extracorporeal membrane oxygenation for left ventricular failure in children: current strategy and clinical outcomes. Artif Organs 2013; 37: 29–36.

40. Baruteau AE, Barnetche T, Morin L, et al. Percutaneous balloon atrial septostomy on top of venoarterial extracorporeal membrane oxygenation results in safe and effective left heart decompression. Eur J Cardiovasc Care 2018; 7: 70–79.

41. Koenig PR, Ralston MA, Kimball TR, Meyer RA, Daniels SR, Schwartz DC. Balloon atrial septostomy for left ventricular decompression in patients receiving extracorporeal membrane oxygenation for myocardial failure. J Pediatr 1993; 122: S95–S99.

42. Hacking DE, Best D, d’Udekem Y, et al. Elective decompression of the left ventricle in pediatric patients may reduce the duration of venoarterial extracorporeal membrane oxygenation. Artif Organs 2015; 39: 319–326.

43. Alhussein M, Osten M, Horlick E, et al. Percutaneous left atrial decompression in adults with refractory cardiogenic shock supported with veno-arterial extracorporeal membrane oxygenation. J Card Surg 2017; 32: 396–401.

44. Haynes S, Kerber RE, Johnson FL, Lynch WR, Divekar A. Left heart decompression by atrial stenting during extracorporeal membrane oxygenation. Int J Artif Organs 2009; 32: 240–242.

45. Eastaugh LJ, Thiagarajan RR, Darst JR, McElhinney DB, Lock JE, Marshall AC. Percutaneous left atrial decompression in patients supported with extracorporeal membrane oxygenation for cardiac disease. Pediatr Crit Care Med 2015; 16: 59–65.
46. Veeram Reddy SR, Guleserian KJ, Nugent AW. Transcatheter removal of atrial septal stent placed to decompress left atrium with VA ECMO. Catheter Cardiovasc Interv 2015; 85: 1021–1025.

47. Cheung MM, Goldman AP, Shekerdemian LS, Brown KL, Cohen GA, Redington AN. Percutaneous left ventricular ‘vent’ insertion for left heart decompression during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2003; 4: 447–449.

48. Aiyouari RM, Rocchini AP, Remenapp RT, Graziano JN. Decompression of the left atrium during extracorporeal membrane oxygenation using a transseptal cannula incorporated into the circuit. Crit Care Med 2006; 34: 2603–2606.

49. Schwartz MF, Smith F, Byrum CJ, Alfieri S. Transseptal catheter decompression of the left ventricle during extracorporeal membrane oxygenation. Pediatr Cardiol 2012; 33: 185–187.

50. Madershahian N, Salehi-Gilani S, Naraghi H, Stoeger W. A simple way to decompress the left ventricle during venoarterial bypass. Thorac Cardiovasc Surg 2008; 56: 337–341.

51. Ward KE, Tuggle DW, Gessouroun MR, Overholt ED, Alkhouri M, Narins CR, Lehoux J, Knight PA, Waits B, Jumean M, Pham DT, Kapur NK. Percutaneous biatrial decompression of the left atrium for venoarterial extracorporeal membrane oxygenation. J Cardiovasc Surg (Torino) 2011; 52: 900.

52. Alkhouri M, Narins CR, Lehous J, Knight PA, Waits B, Ling FS. Percutaneous decompression of the left ventricle in cardiogenic shock patients on venoarterial extracorporeal membrane oxygenation. J Card Surg 2016; 31: 177–182.

53. Ward KE, Tuggle DW, Gessouroun MR, Overholt ED, Mantor PC. Transseptal decompression of the left heart during ECMO for severe myocarditis. Ann Thorac Surg 1995; 59: 749–751.

54. Morishita A, Kitamura M, Shibuya M, Kurihara H, Koyanagi H. Effectiveness of transaortic venting from a failing left ventricle during venoarterial bypass. ASAIO J 1999; 45: 69–73.

55. Barbone A, Malvindi PG, Ferrara P, Tarelli G. Left ventricle unloading by percutaneous pigtail during extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg 2011; 13: 293–295.

56. Fumagalli R, Bombino M, Borelli M, et al. Percutaneous bridge to heart transplantation by venoarterial ECMO and transaortic left ventricular venting. Int J Artif Organs 2004; 27: 410–413.

57. Kolobow T, Rossi F, Borelli M, Foti G. Long-term closed chest partial and total cardiopulmonary bypass by peripheral cannulation for severe right and/or left ventricular failure, including ventricular fibrillation. The use of a percutaneous spring in the pulmonary artery position to decompress the left heart. ASAIO Trans 1988; 34: 485–489.

58. von Segesser LK, Kwang K, Tozzi P, Horisberger J, Dembisky W. A simple way to decompress the left ventricle during venoarterial bypass. Thorac Cardiovasc Surg 2008; 56: 337–341.

59. Fouilloux V, Lebrun L, Mace L, Kreitmann B. Extracorporeal membranous oxygenation and left atrial decompression: a fast and minimally invasive approach. Ann Thorac Surg 2011; 91: 1996–1997.

60. Avalli L, Maggioni E, Sangalli F, Favini G, Formica F, Fumagalli R. Percutaneous left-heart decompression during extracorporeal membrane oxygenation: an alternative to surgical and transeptal venting in adult patients. ASAIO J 2011; 57: 38–40.

61. Gulettek B, Ersoy O, Akkaya I, Kayipmaz C, Pirat A, Sezgin A. Decompression of left ventricle during venoarterial extracorporeal membrane oxygenation support as a step to transplant. Exp Clin Transplant 2016; 14: 42–44.

62. Koul B, Willen H, Sjoberg T, Wetterberg T, Kugelberg J, Steen S. Pulmonary sequelae of prolonged total venaarterial bypass: evaluation with a new experimental model. Ann Thorac Surg 1991; 51: 794–799.

63. Kimura M, Kinoshita O, Fujimoto Y, et al. Central extracorporeal membrane oxygenation requiring pulmonary arterial venting after near-drowning. Am J Emerg Med 2014; 32: 197 e1–2.

64. Guirgis M, Kumar K, Menkis AH, Freed DH. Minimally invasive left-heart decompression during venoarterial extracorporeal membrane oxygenation: an alternative to a percutaneous approach. Interact Cardiovasc Thorac Surg 2010; 10: 672–674.

65. Weymann A, Schmack B, Sabashnikov A, et al. Central extracorporeal life support with left ventricular decompression for the treatment of refractory cardiogenic shock and lung failure. J Cardiothorac Surg 2014; 9: 60.

66. Babu A. Techniques for venoarterial extracorporeal membrane oxygenation support and conversion to temporary left ventricular assist device. Operative Techniques in Thoracic and Cardiovascular Surgery 2019; 19: 365–379.

67. Tepper S, Masood ME, Baltazar Garcia M, et al. Left ventricular unloading by Impella device versus surgical vent during extracorporeal life support. Ann Thorac Surg 2017; 104: 861–867.

68. Saeed D, Stosik H, Islamovic M, et al. Femoro-femoral vs. atrio-aortic extracorporeal membrane oxygenation for cardiogenic shock and lung failure. J Cardiothorac Surg 2014; 9: 60.

69. Chen YS, Ko WJ, Chou TF, et al. Conversion of extracorporeal membrane oxygenation to non-pulsatile left ventricular assist device. Is it out-of-date for non-pulsatile LVAD? J Cardiovasc Surg (Torino) 2001; 42: 457–463.

70. Aggarwal A, Modi S, Kumar S, et al. Use of a single-circuit CentriMag(R) for biventricular support in postpartum cardiomyopathy. Perfusion 2013; 28: 156–159.

71. Soleimani B, Pae WE. Management of left ventricular distension during peripheral extracorporeal membrane oxygenation for cardiogenic shock. Perfusion 2012; 27: 326–331.

72. Eliot J, Gaudard P, Zeroux N, et al. Effect of Impella during veno-arterial extracorporeal membrane oxygenation on pulmonary artery flow as assessed by end-tidal carbon dioxide. ASAIO J. 2018; 64: 502-507.
73. den Uil CA, Dos Reis Miranda D, Van Mieghem NM, Jewbali LS. A Niche indication for intra-aortic balloon pump counterpulsation: aortic valve opening in a surgically vented left ventricle on venoarterial ECMO. JACC Cardiovasc Interv 2017; 10: e133-e134.
74. Greco GC B, Avalli L. Left ventricular rest and unloading during VA ECMO. In: Sangalli F, Patroniti N, Presenti A (eds) ECMO-Extracorporeal Life Support in Adults. Milan, Springer, 2014, pp. 193–206.
75. Meani P, Gelsomino S, Natour E, et al. Modalities and effects of left ventricle unloading on extracorporeal life support: a review of the current literature. Eur J Heart Fail 2017; 19: 84–91.
76. Broomé M, Maksuti E, Bjallmark A, Frenckner B, Janerot-Sjoberg B. Closed-loop real-time simulation model of hemodynamics and oxygen transport in the cardiovascular system. Biomedical Engineering Online 2013; 12: 69.